Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
GSK plc stock logo
GSK
GSK
$36.49
-6.5%
$37.63
$31.72
$45.93
$75.53B0.564.51 million shs10.60 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$737.56
-6.5%
$848.36
$692.96
$972.53
$699.33B0.513.31 million shs5.29 million shs
Perrigo Company plc stock logo
PRGO
Perrigo
$26.31
-2.2%
$26.41
$23.14
$33.46
$3.59B0.491.50 million shs3.24 million shs
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
$12.37
-6.6%
$13.33
$12.36
$16.89
$10.32B0.511.34 million shs3.93 million shs
Sanofi stock logo
SNY
Sanofi
$51.98
-4.8%
$55.37
$45.22
$60.12
$131.92B0.572.28 million shs3.16 million shs
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
$13.83
-6.9%
$16.52
$12.51
$22.80
$15.68B0.829.71 million shs18.09 million shs
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
$524.94
-2.9%
$509.24
$436.38
$630.73
$480.17B0.614.24 million shs9.91 million shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
GSK plc stock logo
GSK
GSK
0.00%-5.81%-8.96%+7.55%-11.41%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.00%-10.09%-15.08%-3.43%-5.95%
Perrigo Company plc stock logo
PRGO
Perrigo
0.00%-6.26%-5.39%+3.69%-16.22%
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
0.00%-6.27%-4.35%-19.90%-16.16%
Sanofi stock logo
SNY
Sanofi
0.00%-6.88%-12.27%+5.67%+10.01%
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
0.00%-8.14%-9.86%-34.24%-2.95%
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
0.00%+1.84%+6.40%+2.54%+15.18%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
GSK plc stock logo
GSK
GSK
2.48 of 5 stars
2.35.02.50.02.40.01.3
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.9013 of 5 stars
3.45.03.34.03.32.51.9
Perrigo Company plc stock logo
PRGO
Perrigo
4.9206 of 5 stars
3.15.04.23.53.12.52.5
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
3.3662 of 5 stars
3.34.01.70.03.50.01.9
Sanofi stock logo
SNY
Sanofi
3.3786 of 5 stars
2.53.02.50.03.50.03.1
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
2.3869 of 5 stars
3.43.00.80.02.70.80.6
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
4.8532 of 5 stars
3.53.04.24.03.53.31.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
GSK plc stock logo
GSK
GSK
2.60
Moderate Buy$43.2518.52% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.84
Moderate Buy$1,009.7236.90% Upside
Perrigo Company plc stock logo
PRGO
Perrigo
2.25
Hold$33.0025.45% Upside
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
2.50
Moderate Buy$17.0037.45% Upside
Sanofi stock logo
SNY
Sanofi
3.00
Buy$62.5020.24% Upside
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
2.86
Moderate Buy$23.4369.40% Upside
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
3.10
Buy$629.3219.88% Upside

Current Analyst Ratings Breakdown

Latest SNY, GSK, TEVA, UNH, LLY, PRGO, and RDY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/21/2025
Sanofi stock logo
SNY
Sanofi
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$65.00
3/6/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$1,146.00
3/6/2025
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$23.00 ➝ $20.00
3/5/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$970.00 ➝ $1,100.00
2/12/2025
GSK plc stock logo
GSK
GSK
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageEqual Weight
2/3/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$1,029.00 ➝ $1,038.00
1/30/2025
Sanofi stock logo
SNY
Sanofi
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
1/30/2025
Sanofi stock logo
SNY
Sanofi
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSell ➝ Hold
1/30/2025
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$30.00 ➝ $27.00
1/30/2025
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$28.00 ➝ $26.00
1/28/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$1,250.00 ➝ $1,190.00
(Data available from 4/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
GSK plc stock logo
GSK
GSK
$31.38B2.41$5.77 per share6.32$8.07 per share4.52
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$45.04B15.53$12.02 per share61.34$15.05 per share49.01
Perrigo Company plc stock logo
PRGO
Perrigo
$4.37B0.82$5.49 per share4.79$35.19 per share0.75
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
$311.31B0.03$0.93 per share13.25$4.50 per share2.75
Sanofi stock logo
SNY
Sanofi
$44.29B2.98$5.12 per share10.16$33.20 per share1.57
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
$16.54B0.95$2.74 per share5.05$4.75 per share2.91
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
$400.28B1.20$33.82 per share15.52$106.78 per share4.92
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
GSK plc stock logo
GSK
GSK
$3.29B$1.5922.957.851.128.13%48.59%11.11%4/30/2025 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$10.59B$11.7162.9923.701.4023.51%85.24%16.19%5/1/2025 (Estimated)
Perrigo Company plc stock logo
PRGO
Perrigo
-$12.70M-$1.25N/A8.60N/A-3.64%7.38%3.18%5/6/2025 (Estimated)
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
$668M$0.6319.6915.08N/A17.25%17.87%12.32%5/6/2025 (Estimated)
Sanofi stock logo
SNY
Sanofi
$6.02B$2.4920.8810.941.0112.77%25.61%14.72%4/24/2025 (Estimated)
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
-$1.64B-$1.45N/A5.261.44-9.91%42.46%6.65%5/7/2025 (Estimated)
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
$14.41B$15.5033.8715.801.373.60%26.69%8.80%4/17/2025 (Estimated)

Latest SNY, GSK, TEVA, UNH, LLY, PRGO, and RDY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2025N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$4.64N/AN/AN/A$12.77 billionN/A
4/30/2025N/A
GSK plc stock logo
GSK
GSK
$1.06N/AN/AN/A$7.52 billionN/A
4/24/2025N/A
Sanofi stock logo
SNY
Sanofi
$0.87N/AN/AN/A$9.79 billionN/A
4/17/2025N/A
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
$7.24N/AN/AN/A$111.56 billionN/A
2/27/2025Q4 2024
Perrigo Company plc stock logo
PRGO
Perrigo
$0.92$0.93+$0.01-$0.32$1.20 billion$1.14 billion
2/6/2025Q4 2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.45$5.32-$0.13$4.88$13.42 billionN/A
2/5/2025Q4 2024
GSK plc stock logo
GSK
GSK
$0.44$0.59+$0.15$0.26$7.75 billionN/A
1/30/2025Q4 2024
Sanofi stock logo
SNY
Sanofi
$0.70$0.70N/A$0.29$10.57 billionN/A
1/29/2025Q4 2024
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
$0.69$0.70+$0.01-$0.19$4.10 billionN/A
1/23/2025Q3 2025
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
$0.19$0.20+$0.01$0.20$975.71 millionN/A
1/16/2025Q4 24
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
$6.74$6.81+$0.07$5.98$101.60 billion$100.81 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
GSK plc stock logo
GSK
GSK
$1.574.30%-17.33%98.74%N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.000.81%+15.21%51.24%11 Years
Perrigo Company plc stock logo
PRGO
Perrigo
$1.164.41%+4.77%N/A 23 Years
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
$0.080.65%N/A12.70%N/A
Sanofi stock logo
SNY
Sanofi
$1.472.83%+1.84%59.04%N/A
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
$1.017.31%N/AN/A N/A
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
$8.401.60%+13.46%54.19%15 Years

Latest SNY, GSK, TEVA, UNH, LLY, PRGO, and RDY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/5/2025
GSK plc stock logo
GSK
GSK
quarterly$0.39324.2%2/21/20252/21/20254/10/2025
2/19/2025
Perrigo Company plc stock logo
PRGO
Perrigo
quarterly$0.294.68%3/7/20253/7/20253/25/2025
2/24/2025
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
quarterly$2.101.8%3/10/20253/10/20253/18/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
GSK plc stock logo
GSK
GSK
1.12
0.78
0.52
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.00
1.15
0.97
Perrigo Company plc stock logo
PRGO
Perrigo
0.94
2.56
1.77
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
0.02
1.92
1.38
Sanofi stock logo
SNY
Sanofi
0.15
1.46
1.14
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
2.97
0.98
0.75
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
0.74
0.83
0.91
CompanyEmployeesShares OutstandingFree FloatOptionable
GSK plc stock logo
GSK
GSK
90,1002.07 billion1.87 billionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
39,000948.17 million948.08 millionOptionable
Perrigo Company plc stock logo
PRGO
Perrigo
8,900136.46 million135.47 millionOptionable
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
24,800834.77 million818.05 millionOptionable
Sanofi stock logo
SNY
Sanofi
91,6002.54 billion2.51 billionOptionable
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
36,8001.13 billion1.13 billionOptionable
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
400,000914.71 million917.25 millionOptionable

Recent News About These Companies

UnitedHealth Group Incorporated stock logo
Top Medical Stocks To Research - April 5th

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
GSK stock logo

GSK NYSE:GSK

$36.49 -2.52 (-6.45%)
Closing price 04/4/2025 03:59 PM Eastern
Extended Trading
$34.71 -1.78 (-4.89%)
As of 09:17 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$737.56 -51.53 (-6.53%)
Closing price 04/4/2025 03:59 PM Eastern
Extended Trading
$694.31 -43.25 (-5.86%)
As of 09:17 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Perrigo stock logo

Perrigo NYSE:PRGO

$26.31 -0.59 (-2.21%)
Closing price 04/4/2025 03:59 PM Eastern
Extended Trading
$25.90 -0.40 (-1.52%)
As of 09:13 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

Dr. Reddy's Laboratories stock logo

Dr. Reddy's Laboratories NYSE:RDY

$12.37 -0.87 (-6.59%)
Closing price 04/4/2025 03:59 PM Eastern
Extended Trading
$12.47 +0.10 (+0.82%)
As of 09:11 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Sanofi stock logo

Sanofi NASDAQ:SNY

$51.98 -2.64 (-4.83%)
Closing price 04/4/2025 04:00 PM Eastern
Extended Trading
$50.74 -1.24 (-2.39%)
As of 09:15 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Teva Pharmaceutical Industries stock logo

Teva Pharmaceutical Industries NYSE:TEVA

$13.83 -1.02 (-6.87%)
Closing price 04/4/2025 03:59 PM Eastern
Extended Trading
$14.64 +0.81 (+5.89%)
As of 09:17 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

UnitedHealth Group stock logo

UnitedHealth Group NYSE:UNH

$524.94 -15.50 (-2.87%)
Closing price 04/4/2025 03:59 PM Eastern
Extended Trading
$518.28 -6.66 (-1.27%)
As of 09:16 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage. The Optum Health segment provides care delivery, care management, wellness and consumer engagement, and health financial services patients, consumers, care delivery systems, providers, employers, payers, and public-sector entities. The Optum Insight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The Optum Rx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and community health pharmacy services, infusion, and purchasing and clinical capabilities, as well as develops programs in the areas of step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated was founded in 1974 and is based in Minnetonka, Minnesota.